Standard BioTools (LAB) Expected to Release Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) is expected to be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Standard BioTools to post earnings of ($0.01) per share and revenue of $20.8040 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Standard BioTools Trading Down 1.5%

LAB stock traded down $0.01 during trading on Tuesday, reaching $0.85. The stock had a trading volume of 128,629 shares, compared to its average volume of 2,752,963. The firm has a fifty day moving average price of $0.90 and a 200 day moving average price of $1.02. The company has a market capitalization of $332.99 million, a P/E ratio of 4.26 and a beta of 1.39. Standard BioTools has a 1-year low of $0.70 and a 1-year high of $1.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Standard BioTools from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 21st. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $1.35.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its stake in shares of Standard BioTools by 862.2% in the 1st quarter. AQR Capital Management LLC now owns 482,912 shares of the company’s stock valued at $522,000 after purchasing an additional 432,725 shares in the last quarter. Creative Planning increased its holdings in Standard BioTools by 56.6% in the second quarter. Creative Planning now owns 61,102 shares of the company’s stock valued at $73,000 after buying an additional 22,082 shares during the last quarter. Legal & General Group Plc raised its stake in Standard BioTools by 25.7% during the second quarter. Legal & General Group Plc now owns 310,435 shares of the company’s stock valued at $373,000 after buying an additional 63,484 shares in the last quarter. Rhumbline Advisers lifted its holdings in Standard BioTools by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 472,981 shares of the company’s stock worth $568,000 after buying an additional 60,220 shares during the last quarter. Finally, Prudential Financial Inc. lifted its holdings in Standard BioTools by 72.7% during the 2nd quarter. Prudential Financial Inc. now owns 39,307 shares of the company’s stock worth $47,000 after buying an additional 16,541 shares during the last quarter. 53.74% of the stock is owned by institutional investors and hedge funds.

Standard BioTools Company Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.